Role and modulation of Zinc-finger antiviral protein and antiviral Regnase-1-like endonucleases

MSCA (Marie Skłodowska-Curie)HORIZON-TMA-MSCA-PF-EFID: 101062524
EC Contribution
€1,738
Consortium Size
1 orgs
Start Year
2022
Summary

The human zinc finger antiviral protein (ZAP) is capable of inhibiting several major human pathogens, including Influenza A virus and SARS-CoV-2. ZAP specifically targets CpG dinucleotides in RNAs and might be one of the reasons why CpGs are strongly suppressed in the human genome. Successful viruses, such as HIV-1 and SARS-CoV-2, mimic human CpG suppression to partially evade the inhibitory effects of ZAP. However, especially under conditions of infection or inflammation when ZAP is expressed at high levels, it inhibits both CpG containing viral as well as cellular RNAs. Importantly, ZAP itself does not possess RNAse activity and is dependent on cofactors, such as KHNYN, to destroy viral RNAs. KHNYN is tightly regulated and inactivated by MALT-1, a cellular protease representing an important target in cancer immunotherapies. Although some progress has been made, the identity of ZAP cofactors as well as their mechanism(s) of action and therapeutic potential are poorly understood. This proposal aims to combine the expertise of the applicant (mechanistic studies of ZAP and RNA-targeting factors) and the host (respiratory viruses and antiviral drug development) to define how ZAP-dependent and independent antiviral endonucleases restrict major respiratory viral pathogens. In addition, it will be examined whether MALT-1 inhibitors that are currently in clinical trials against cancers allow to enhance and maintain the antiviral activity of ZAP and its cofactors thus offering prospects for the treatment of respiratory infections. Finally, potential side-effects on cellular RNAs and their impact on immune signalling, cell activation and infection outcome will be determined. The project will combine innovative CRISPR/Cas9 genome editing, in vitro virus infection platforms, novel functional assays and state-of-the-art deep sequencing technologies to significantly advance the knowledge on antiviral RNAses and to clarify whether they can be strengthened for antiviral therapy.

Consortium (1)

Project Results (7)

Source: CORDIS, the EU research results database.

Publications (4)
Antiviral factors and their counteraction by HIV-1: many uncovered and more to be discovered
Journal of Molecular Cell Biology· 2024DOI
Dorota Kmiec, Frank Kirchhoff
Scientific Reports
Scientific Reports· 2024DOI
Asimenia Vlachou; Rayhane Nchioua; Kerstin Regensburger; Frank Kirchhoff; Dorota Kmiec
Reduced replication but increased interferon resistance of SARS-CoV-2 Omicron BA.1
Life Science Alliance· 2023DOI
Rayhane Nchioua; Annika Schundner; Susanne Klute; Lennart Koepke; Maximilian Hirschenberger; Sabrina Noettger; Giorgio Fois; Fabian Zech; Alexander Graf; Stefan Krebs; Peter Braubach; Helmut Blum; Steffen Stenger; Dorota Kmiec; Manfred Frick; Frank Kirchhoff; Konstantin MJ Sparrer
Viruses
Viruses· 2023DOI
Elena Hagelauer; Rishikesh Lotke; Dorota Kmiec; Dan Hu; Mirjam Hohner; Sophie Stopper; Rayhane Nchioua; Frank Kirchhoff; Daniel Sauter; Michael Schindler
Deliverables (2)
Other Results (1)
Periodic Reporting for period 1 - EXPL ANTIVIR ENDONUC (Role and modulation of Zinc-finger antiviral protein and antiviral Regnase-1-like endonucleases)